evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,805 questions · 2,912 findings · 307 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 706 · 24.2%GRADE not reported 133 · 4.6%Very low 786 · 27%Low 696 · 23.9%Moderate 474 · 16.3%High 117 · 4%

Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications)

Complete clearance · people with scabies, 2 to 80 years of ageLocation: India, Pakistan

Oral ivermectin 200 μg/kg (1 to 3 doses) may leads to lower complete clearance ‐ week 1 compared with topical permethrin 5% cream (1 to 3 applications) (low certainty).

5 findings from 1 review
Show 2 more findings

Oral ivermectin 200 μg/kg (1 to 2 doses) vs topical permethrin 5% lotion (1 to 5 applications)

Complete clearance · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan

Oral ivermectin 200 μg/kg (1 to 2 doses) showed no clear difference in complete clearance ‐ week 1 ‐ IVER 1 dose versus PER on 5… compared with topical permethrin 5% lotion (1 to 5 applications) (low certainty).

4 findings from 1 review
Show 1 more finding

Oral ivermectin 200 μg/kg (1 to 2 doses) vs topical permethrin 5% lotion (1 to 5 applications)

Number of participants with ≥ 1 AE ‐ week 2 ‐ IVER 2 doses versus PER on 5 consecutive nights · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan

It is very uncertain whether oral ivermectin 200 μg/kg (1 to 2 doses) changes number of participants with ≥ 1 AE ‐ week 2 ‐ IVER 2 doses versus… compared with topical permethrin 5% lotion (1 to 5 applications) (very low certainty).

1 finding from 1 review

Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical ivermectin 1% lotion/solution (1 to 3 applications)

Complete clearance · people with scabies, 5 to 80 years of ageLocation: Egypt, India

Oral ivermectin 200 μg/kg (1 to 3 doses) showed no clear difference in complete clearance ‐ week 1 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (low certainty).

3 findings from 1 review

Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical ivermectin 1% lotion/solution (1 to 3 applications)

Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: Egypt, India

It is very uncertain whether oral ivermectin 200 μg/kg (1 to 3 doses) changes number of participants with ≥ 1 AE ‐ week 4 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (very low certainty).

1 finding from 1 review

Topical ivermectin vs topical permethrin 5% cream (1 to 3 applications)

Complete clearance · people with scabies, 5 to 80 years of ageLocation: India

Topical ivermectin 1% lotion (1 to 3 applications) showed no clear difference in complete clearance ‐ week 4 compared with topical permethrin 5% cream (1 to 3 applications) (moderate certainty).

1 finding from 1 review

Topical ivermectin vs topical permethrin 5% cream (1 to 3 applications)

Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: India

It is very uncertain whether topical ivermectin 1% lotion (1 to 3 applications) changes number of participants with ≥ 1 AE ‐ week 4 compared with topical permethrin 5% cream (1 to 3 applications) (very low certainty).

1 finding from 1 review

Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications)

Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 2 to 80 years of ageLocation: India, Pakistan

Oral ivermectin 200 μg/kg (1 to 3 doses) showed no clear difference in number of participants with ≥ 1 AE ‐ week 4 compared with topical permethrin 5% cream (1 to 3 applications) (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review